J Stroke.  2017 Sep;19(3):347-355. 10.5853/jos.2017.00395.

Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

• Seiffge DJ
• Traenka C
• Polymeris
• Thilemann
• Wagner B
• Hert L
• Müller MD
• Gensicke H
• Peters N
• Nickel CH
• Stippich C
• Sutter R
• Marsch S
• Fisch U
• Guzman R
• De Marchis GM
• Lyrer PA
• Bonati LH
• Tsakiris D
• Engelter S

• KMID: 2408401
• DOI: http://doi.org/10.5853/jos.2017.00395

Abstract

BACKGROUND AND PURPOSE
Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis (IVT) or endovascular treatment (EVT).
METHODS
This was a single-center explorative analysis using data from the Novel-Oral-Anticoagulants-in-Stroke-Patients-registry (clinicaltrials.gov:NCT02353585) including acute stroke patients taking rivaroxaban (September 2012 to November 2016). The SOP included recommendation, consideration, and avoidance of IVT if rivaroxaban plasma levels were < 20 ng/mL, 20"’100 ng/mL, and >100 ng/mL, respectively, measured with a calibrated anti-factor Xa assay. Patients with intracranial artery occlusion were recommended IVT+EVT or EVT alone if plasma levels were ≤100 ng/mL or >100 ng/mL, respectively. We evaluated the frequency of IVT/EVT, door-to-needle-time (DNT), and symptomatic intracranial or major extracranial hemorrhage.
RESULTS
Among 114 acute stroke patients taking rivaroxaban, 68 were otherwise eligible for IVT/EVT of whom 63 had plasma levels measured (median age 81 years, median baseline National Institutes of Health Stroke Scale 6). Median rivaroxaban plasma level was 96 ng/mL (inter quartile range [IQR] 18"’259 ng/mL) and time since last intake 11 hours (IQR 4.5"’18.5 hours). Twenty-two patients (35%) received IVT/EVT (IVT n=15, IVT+EVT n=3, EVT n=4) based on SOP. Median DNT was 37 (IQR 30"’60) minutes. None of the 31 patients with plasma levels >100 ng/mL received IVT. Among 14 patients with plasma levels ≤100 ng/mL, the main reason to withhold IVT was minor stroke (n=10). No symptomatic intracranial or major extracranial bleeding occurred after treatment.
CONCLUSIONS
Determination of rivaroxaban plasma levels enabled IVT or EVT in one-third of patients taking rivaroxaban who would otherwise be ineligible for acute treatment. The absence of major bleeding in our pilot series justifies future studies of this approach.

Keyword

Rivaroxaban; Stroke; Plasma levels; Thrombolysis

MeSH Terms

Arteries
Hemorrhage
Humans
National Institutes of Health (U.S.)
Plasma*
Rivaroxaban*
Stroke*
Rivaroxaban